Patent · US Active

Fusokines involving cytokines with strongly reduced receptor binding affinities

US10640542B2 · kind B2 · utility

17Cited by

3References

6Claims

0Family size

Assignees

VIB VZW · BE
UNIVERSITEIT GENT · BE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
Université Montpellier · FR
Centre Hospitalier Regional Universitaire de Montpellier · FR

Inventors

Jan Tavernier · Balegem, BE
Jennyfer Bultinck · Ledeberg, BE
Sarah Gerlo · Wondelgem, BE
Gilles Uze · Montpellier, FR
Franciane Paul · Montpellier, FR
Yann Bordat · Montpellier, FR

Key dates

Filing date	Jul 3, 2014
Grant date	May 5, 2020
Priority date	—
Expiry date	Nov 28, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.